Starpharma EV/EBITDA
¿Qué es el EV/EBITDA de Starpharma?
El EV/EBITDA de Starpharma Holdings Limited es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en ASX en comparadas con Starpharma
¿Qué hace Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Empresas con ev/ebitda similar a Starpharma
- AuMake International tiene EV/EBITDA de N/A
- Hydoo International tiene EV/EBITDA de N/A
- Damara Gold tiene EV/EBITDA de N/A
- Kairos Minerals tiene EV/EBITDA de N/A
- TVI Pacific tiene EV/EBITDA de N/A
- Aurion Resources tiene EV/EBITDA de N/A
- Starpharma tiene EV/EBITDA de N/A
- Diagnostic Medical Systems S.A tiene EV/EBITDA de N/A
- Xelpmoc Design and Tech tiene EV/EBITDA de N/A
- Just Plc tiene EV/EBITDA de N/A
- M&L tiene EV/EBITDA de N/A
- Takeaway.com NV tiene EV/EBITDA de N/A
- Just Eat Takeaway.com N.V tiene EV/EBITDA de N/A